The pharmacotherapy of sickle cell disease

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 3069-3082

  Wang, Winfred C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Butyrate; Decitabine; Hemoglobin F; Hydroxycarbamide; Pharmacotherapy; Sickle cell

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ARGININE; BUTYRIC ACID; CLOTRIMAZOLE; CORTICOSTEROID; DIPYRIDAMOLE; ENALAPRIL; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; I KAPPA B; ION CHANNEL; NIPRISAN; NITRIC OXIDE; NIX 0699; PENICILLIN G; PLACEBO; PLANT EXTRACT; POLOXAMER; PYROGLUTAMATE MAGNESIUM; RIBONUCLEOTIDE REDUCTASE; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG; ZINC;

ACUTE CHEST SYNDROME; ARTERY OCCLUSION; CELL DENSITY; CELL MEMBRANE CONDUCTANCE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTINUOUS INFUSION; DNA METHYLATION; DOPPLER ECHOGRAPHY; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; ERYTHROID PRECURSOR CELL; GELATION; GROWTH RATE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SYNTHESIS; HEMOLYSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE INFERTILITY; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OXYGEN SATURATION; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; POLYMERIZATION; PRIAPISM; PROTEINURIA; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SPLEEN FUNCTION; STEM CELL TRANSPLANTATION; TERATOGENICITY;

ANEMIA, SICKLE CELL; ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG THERAPY, COMBINATION; FETAL HEMOGLOBIN; HUMANS; NITRIC OXIDE; PLANT EXTRACTS;

EID: 57549100846     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802519878     Document Type: Review

References (130)

1. Pauling L, Itano HA, Singer SJ, et al. Sickle-cell anemia: a molecular disease. Science 1949;110:543-7
2. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci 2006;27:204-10
3. Wanko SO, Telen MJ. Transfusion management in sickle cell disease. Hematol Oncol Clin North Am 2005;19:803-26 [PubMed: 16214645]
4. Taher A. Iron overload in thalassemia and sickle cell disease. Semin Hematol 2005;42:S5-9 [PubMed: 15846583]
5. Cohen AR. New advances in iron chelation therapy. ASH Education Book; 2006;42-7
6. Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant 2008;41:109-17 [PubMed: 1805933]
7. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anaemia. N Engl J Med 1986;314:1593-9
8. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-53
9. Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin N Am 2005;19:917-28
10. Aoki RY, Saad STO. Enalapril reduced the albuminuria of patients with sickle cell disease. Am J Med 1995;98:432-5
11. Prasad AS, Cossack ZT. Zinc supplementation and growth in sickle cell disease. Ann Intern Med 1984;100:367-71
12. Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998;92:3082-9
13. Benjamin LJ, Payne R. Pain in sickle cell disease: a multidimensional construct. In: Pace B, editor,. Renaissance of sickle cell disease research in the genomic era. London: Imperial College Press; 2007. p. 99-118
14. Ballas SK. Current issues in sickle cell pain and its management. ASH Education Book; 2007:97-105
15. Ballas SK. Progress in pain research and management. In: Sickle cell pain. Volume 11. IASP Press, Seattle, WA, USA; 1998;149-237
16. Dean J, Schechter AN. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches. N Engl J Med 1978;299:863-70
17. Raphael RI, Vichinsky EP. Pathophysiology and treatment of sickle cell disease. Clin Adv Hematol Oncol 2005;3:492-505
18. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004;103:4023-7
19. Powars DR, Weiss JN, Chan LS, et al. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 1984;63:921-6
20. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-16
21. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19:1-10
22. Dover GJ, Humphries RK, Moore JG, et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 1986;67:735-8
23. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-6
24. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555-65
25. Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002;116:436-44
26. Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996;88:4701-10
27. Hillery CA, Du MC, Wang WC, et al. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000;109:322-7
28. Desimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 1982;7:4428-31
29. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-22
30. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-51
31. Debaun MR, Field JJ. Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) Trial. ASH Education Book; 2007;482-8
32. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a Phase I/II trial. Blood 1999;94:1550-4
33. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia - the HUSOFT extension study. Blood 2005;106:2264-75
34. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin N Am 2008;55:483-501
35. Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 1996;88:1951-3
36. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 1998;20:26-31
37. Hankins J, Helton K, Mc Carville B, et al. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer 2008;50:293-7
38. ClinicalTrials.gov. Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG). Available from: http://clinicaltrials.gov/ct2/show/NCT00006400 [Last accessed 27 October 2008]
39. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94:3022-6
40. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004;145:346-52
41. Sumoza A, De Bisotti R, Sumoza D, et al. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 2002;71:161-5
42. ClinicalTrials.gov. Stroke with transfusions changing to hydroxyurea (SWiTCH). Available from: http://clinicaltrials.gov/ct2/show/NCT00122980 [Last accessed 27 October 2008]
43. Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007;110:1043-7
44. Kratovil T, Bulas D, Driscol MC, et al. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer 2006;47:894-900
45. Lefévre N, Dufour D, Gulbis B, et al. Use of hydroxyurea in prevention of stroke in children with sickle cell disease. Blood 2008;111:963-4
46. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 2005;105:2685-90
47. Bernaudin F, Verlhac S, Coic L, et al. Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol 2005;35:242-8
48. Puffer E, Schatz J, Roberts CW. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease. Child Neuropsychol 2007;13:142-54
49. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95
50. Singh SA, Koumbourlis AC, Aygun B. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. Pediatr Blood Cancer 2008;50:1258-60
51. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer 2005;47:982-5
52. Saad ST, Lajolo C, Gilli S, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol 2004;77:45-9
53. Maples BL, Hagemann TM. Treatment of priapism in pediatric patients with sickle cell disease. Am J Health Syst Pharm 2004;61:355-63
54. Venigalla P, Motwani B, Nallari A, et al. A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection. Blood 2002;100:363
55. Chaine B, Neonato MG, Girot R, et al. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 2001;137:467-70
56. O'branski EE, Ware RE, Pose NS, et al. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. J Am Acad Dermatol 2001;44:859-61
57. Wang W, Helms RW, Lynn HS, et al. The effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr 2002;140:225-9
58. De Montalembert M, Bégué P, Bernaudin F, et al. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child 1999;81:437-9
59. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med 2000;133:925-6
60. Moschovi M, Psychou F, Menegas D, et al. Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea. Pediatr Hematol Oncol 2001;18:371-6
61. De Montalembert M, Davies SC. Is hydroxyurea leukemogenic in children with sickle cell disease? Blood 2001;98:2878-9
62. Aliverti V, Bonanomi L, Giavini E. Hydroxyurea as a reference standard in teratological screening: comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administration to pregnant rats. Arch Toxicol 1980;4(suppl 4):239-47
63. Byrd DC, Pitts SR, Alexander CK. Hydroxyurea in two pregnant women with sickle cell anemia. Pharmacotherapy 1999;19:1459-62
64. Khayat AS, Antunes LM, Guimarães AC, et al. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea. Clin Exp Med 2006;6:33-7
65. Friedrisch JR, Prá D, Maluf SW, et al. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res 2008;649:213-20
66. Hanft VN, Fruchtman SR, Pickens CV, et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 2000;95:3589-93
67. Masood J, Hafeez A, Hughes A, et al. Hydroxyurea therapy: a rare cause of reversible azoospermia. Int Urol Nephrol 2007;39:905-7
68. Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 2007;37:190-2
69. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematolagica 2008;93:988-93
70. De Montalembert M, Bachir D, Hulin A, et al. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. Haematologica 2006;91:1685-8
71. Yan JH, Ataga K, Kaul S, et al. The influence of renal function an hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol 2005;45:434-45
72. Bachir D, Hulin A, Huet E, et al. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. Hemoglobin 2007;31:417-25
73. Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000;96:2379-84
74. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine in fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003;102:3865-70
75. Saunthararajah Y. Decitabine and sickle cell disease: molecular therapy for a molecular disease. Pediatr Hematol Oncol 2007;24:465-8
76. Perrine SP, Faller DV. Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the β-hemoglobinopathies. Experientia 1993;49:133-7
77. Weinberg RS, Ji X, Sutton M, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 2005;105:1807-9
78. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 1993;328:81-6
79. Sher GD, Ginder GD, Little J, et al. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. N Engl J Med 1995;332:1606-10
80. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93:1790-7
81. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994;84:339-43
82. Resar LMS, Segal JB, Fitzpatric LK, et al. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol 2002;24:737-41
83. Kieslich M, Schwabe D, Cinatl J Jr, et al. Increase of fetal hemoglobin synthesis indicating differentiation in children receiving valproic acid. Pediatr Hematol Oncol 2003;20:15-22
84. Rönndahl G, Mönkemeyer S, Schulze S, et al. Novel valproic acid derivatives with hemoglobin F inducing activity. Am J Hematol 2006;81:374-6
85. Rosa RM, Bierer BE, Thomas R, et al. A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. N Engl J Med 1980;303:1138-43
86. Brugnara C. Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. J Pediatr Hematol Oncol 2003;25:927-33
87. Alverez J, Montero M, Garcia-Sancho J. High affinity inhibition of Ca2+-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem 1992;267:11789-93
88. De Franceschi L, Saadane N, Trudel M, et al. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J Clin Invest 1994;93:1670-6
89. Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008;111:3991-7
90. Olukoga AO, Adewoye HO, Erasmus RT, et al. Erythrocyte and plasma magnesium in sickle-cell anaemia. East Afr Med J 1990;67:348-54
91. Ortiz OE, Lew VI, Bookchim RM. Deoxygenation permeabilizes sickle cell anaemia red cells to magnesium and reverses its gradient in the dense cells. J Physiol 1990;427:211-26
92. Brugnara C, Tosteson DC. Inhibition of K transport by divalent cations in sickle erythrocytes. Blood 1987;70:1810-5
93. De Franceschi L, Beuzard Y, Jouault H, et al. Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. Blood 1996;88:2738-44
94. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997;100:1847-52
95. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol 2000;108:284-9
96. Joiner CH, Jiang M, Claussen WJ, et al. Dipyridamole inhibits sickling-induced cation fluxes in sickle red blood cells. Blood 2001;97:3976-83
97. Rodgers GP, Dover GJ, Uyesaka N, et al. Augmentation by erythropoietin of the fet al-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 1993;328:73-80
98. El-Hazmi MA, Al-Momen A, Kandaswam YS, et al. On the use of hydroxyurea/ erythropoietin combination therapy for sickle cell disease. Acta Haematol 1995;94:128-34
99. Little JA, McGowan VR, Kato GJ, et al. Combination of erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 2006;91:1076-83
100. Choi SH, Byun HM, Kwan JM, et al. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 2007;138:616-23
101. ClinicalTrials.gov. Effectiveness of hydroxyurea and magnesium pidolate alone and in combination in hemoglobin SC disease: a Phase II trial (CHAMPS). Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00532883
102. Gladwin MT. Unraveling the hemolytic subphenotype of sickle cell disease. Blood 2005;106:2925-6
103. Lopez BL, Davis-Moon L, Ballas SK, Ma XL. Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis. Am J Hematol 2000;64:15-9
104. Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000;22:515-20
105. Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. J Am Med Assoc 2003;289:1136-42
106. Atz AM, Weasel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997;87:988-90
107. Sullivan KJ, Goodwin SR, Evangelist J, et al. Nitric oxide successfully used to treat acute cheat syndrome of sickle cell disease in a young adolescent. Crit Care Med 1999;27:2563-668
108. Styles L, Kuypers F, Kesler K, et al. Arginine therapy does not benefit children with sickle cell anemia - results of the CSCC Clinical Trial Consortium Multi-Institutional Study. Blood 2007;118:668a
109. Mack AK, McGowan VR II, Tremonti CK, et al. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a Phase I/II study. Br J Haematol 2008;142:971-8
110. Ballas SK, Files B, Luchtman-Jones L, et al. Safety of purified poloxamer 188 in sickle cell disease: Phase I study of a nonionic surfactant in the management of acute chest syndrome. Hemoglobin 2004;28:85-102
111. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA 2001;286:2099-206
112. Kaul DK, Liu XD, Choong S, et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2004;287:H293-301
113. Solovey AA, Solovey AN, Harkness J, et al. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001;97:1937-41
114. Osamo NO, Photiades DP, Famodu AA. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 1981;66:102-7
115. Greenberg J, Ohene-Frempong K, Halus J, et al. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 1983;102:781-4
116. Zago MA, Costa FF, Ismael SJ, et al. Treatment of sickle cell diseases with aspirin. Acta Haematol 1984;72:61-4
117. Semple MJ, Al-Hasani SF, Kioy P, et al. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984;51:303-6
118. Cabannes R, Lonsdorfer J, Castaigne JP, et al. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 1984;15:199-212
119. Schnog JB, Kater AP, MacGillavry MR, et al. Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am J Hematol 2001;68:179-83
120. Osarogiagbon UR, Choong S, Belcher JD, et al. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000;96:314-20
121. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83-9
122. West MS, Wethers D, Smith J, et al. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol 1992;45:893-909
123. Adler BK, Salzman DE, Carabasi MH, et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001;97:3313-4
124. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction its a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 2001;97:3998-9
125. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive 'switching' agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine 1996;75:300-26
126. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with SCD. N Engl J Med 1994;330:733-7
127. Clinical. Trials.gov. Randomized trial or oral dexamethasone for acute chest syndrome. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00530270 [Last accessed 27 October 2008]
128. Iyamu LW, Turner LA, Asakura T. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol 2003;122:1001-8
129. Wambebe C, Khamofu H, Momoh JAF, et al. Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN® in patients with sickle cell disorder. Phytomedicine 2001;8:252-61
130. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference Statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008;148:1-9